Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.01. | Absci Corporation: Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference | 1 | GlobeNewswire (USA) | ||
ABSCI Aktie jetzt für 0€ handeln | |||||
28.12.22 | Absci Corporation: Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference | 2 | GlobeNewswire (USA) | ||
16.12.22 | Absci Corp - 8-K, Current Report | 1 | SEC Filings | ||
23.11.22 | Absci Corporation: Absci to Participate in the Berenberg Discover AI Seminar | 1 | GlobeNewswire (USA) | ||
17.11.22 | Absci Corporation: Absci to Participate in the Piper Sandler Healthcare Conference | - | GlobeNewswire (USA) | ||
09.11.22 | Absci Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
09.11.22 | Absci Corp - 8-K, Current Report | 1 | SEC Filings | ||
09.11.22 | Absci GAAP EPS of -$0.30 misses by $0.02, revenue of $2.37M beats by $0.5M | - | Seeking Alpha | ||
09.11.22 | Absci Corporation: Absci Reports Third Quarter 2022 Financial Results | 196 | GlobeNewswire (Europe) | Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09... ► Artikel lesen | |
02.11.22 | Absci Corporation: Absci to Participate in the Stifel Healthcare Conference | - | GlobeNewswire (USA) | ||
26.10.22 | Absci Corporation: Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference | 6 | GlobeNewswire (USA) | ||
04.10.22 | Absci Corp - 8-K, Current Report | 2 | SEC Filings | ||
04.10.22 | Absci Corporation: Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer | 2 | GlobeNewswire (USA) | ||
20.09.22 | Absci Corp - 8-K, Current Report | 1 | SEC Filings | ||
30.08.22 | Pre-market Movers: Mobile Global Esports, Sentage Holdings, FREYR Battery, Bed Bath & Beyond, Absci | 890 | AFX News | UNION (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET).In the Green Mobile Global Esports Inc. (MGAM) is up over 27% at... ► Artikel lesen | |
24.08.22 | ABSCI Corporation: Absci to Participate at the Inaugural Gilmartin Group Emerging Growth Company Showcase | - | GlobeNewswire (USA) | ||
12.08.22 | Absci sees double downgrade at JPMorgan on concerns over product mix | 2 | Seeking Alpha | ||
11.08.22 | Absci up as much as 37% after saying it has enough cash to operate through 2025 | 2 | Seeking Alpha | ||
11.08.22 | Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M | - | Seeking Alpha | ||
11.08.22 | Absci Corp - 10-Q, Quarterly Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 158,02 | -0,38 % | Opening Bell: General Electric, Lithium Americas, McDonald's, Spotify, Caterpillar, Moderna, AMD | Am Mittwoch wird die amerikanische Notenbank ihren jüngsten Zinsentscheid gekannt geben. Im Vorfeld meideten die Anleger in den USA gestern das Risiko. Der Nasdaq 100 verlor über zwei Prozent. Der Dow... ► Artikel lesen | |
NOVAVAX | 10,242 | +0,12 % | Novavax geht richtig ab! | Mit viel Vorschusslorbeeren startet Novavax in den heutigen Handel. So springt der Kurs um rund vier Prozent nach oben. Ein Platz unter den Tagesbesten ist damit schon jetzt gesichert. Startet jetzt... ► Artikel lesen | |
BIOGEN | 264,70 | -0,28 % | Biogen Inc.: Lecanemab Receives Priority Review Status in Japan | TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 689,60 | -0,04 % | Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent | PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Dupixent... ► Artikel lesen | |
OCUGEN | 1,132 | -2,46 % | Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met | Study met both co-primary endpoints with robust immune responses COVAXIN was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in... ► Artikel lesen | |
CANSINO BIOLOGICS | 7,798 | -1,52 % | CANSINOBIO (06185): INSIDE INFORMATION RESULTS FORECAST FOR THE YEAR 2022 | ||
HUMANIGEN | 0,170 | +8,90 % | Humanigen Reports Third Quarter 2022 Financial Results | Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in... ► Artikel lesen | |
NEOGENOMICS | 11,330 | -0,46 % | Analyst Expectations for NeoGenomics' Future | ||
G1 THERAPEUTICS | 7,388 | -0,59 % | G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RELAY THERAPEUTICS | 21,680 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights | Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,515 | 0,00 % | Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB | SALT LAKE CITY, Oct. 25, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it... ► Artikel lesen | |
CANDEL THERAPEUTICS | 2,420 | -6,20 % | Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights | Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in... ► Artikel lesen | |
BENEVOLENTAI | 3,580 | 0,00 % | BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis | BEN-8744 demonstrates the potential of the Benevolent Platform? to uncover novel targets not previously linked to a given disease Initiation of Phase I clinical trial is planned for H1... ► Artikel lesen | |
EVOTEC | 18,915 | +5,82 % | EQS-News: Evotec SE: Evotec gibt Vereinbarung mit Janssen zur Entwicklung von immunbasierten Therapien bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Vereinbarung mit Janssen zur Entwicklung von immunbasierten Therapien bekannt
26.01.2023 / 07:30 CET/CEST
Für den Inhalt... ► Artikel lesen | |
QIAGEN | 44,920 | +0,20 % | Märkte am Morgen: WTI, American Express, Visa, PayPal, Qiagen, Deutsche Bank, Commerzbank, BVB | Der DAX hat eine bewegungsarme Woche hinter sich. Immerhin ging es unter dem Strich leicht nach oben. Heute deutet sich zum Handelsstart ein kleines Minus an. Die Vorgaben aus Asien sind durchwachsen.... ► Artikel lesen |